Peripheral Arterial Disease Pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Arterial Disease treatment therapies, analyzes DelveInsight.
Peripheral Arterial Disease Overview:
Peripheral artery disease (PAD) affects an estimated 200 million people globally, with prevalence increasing significantly among individuals over the age of 50. In the United States alone, around 8.5 million people are affected, particularly those with diabetes or a history of smoking. The global rise in PAD cases is largely driven by aging populations and an increase in risk factors such as obesity and high blood pressure.
PAD is a circulatory disorder in which narrowed arteries—usually due to atherosclerosis—limit blood flow to the limbs, most often the legs. Common symptoms include leg pain while walking (claudication), numbness, cold sensations, slow-healing wounds, and changes in skin color. If left untreated, PAD can lead to serious complications like heart attacks, strokes, or even limb amputation.
Major risk factors include smoking, diabetes, high blood pressure, elevated cholesterol, obesity, sedentary lifestyle, and aging. Diagnosis typically involves a review of medical history, physical examination, and tests such as the Ankle-Brachial Index (ABI), Doppler ultrasound, and angiography.
Treatment focuses on restoring proper blood flow, easing symptoms, and avoiding complications. Core strategies include lifestyle modifications—such as quitting smoking, maintaining a balanced diet, and regular physical activity—alongside medications to control associated conditions. In more advanced cases, surgical interventions like angioplasty or bypass surgery may be necessary. Ongoing monitoring and follow-up care are essential for effective long-term management.
Download our report @ https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Peripheral Arterial Disease Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Peripheral Arterial Disease Therapeutics Market.
Key Takeaways from the Peripheral Arterial Disease Pipeline Report
DelveInsight’s Peripheral Arterial Disease pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Peripheral Arterial Disease treatment.
On November 4, 2024, R3 Vascular, a U.S.-based company, obtained FDA approval for an investigational device exemption (IDE) to launch the pivotal ELITE-BTK trial. This trial will assess the effectiveness of its bioabsorbable scaffold treatment for peripheral arterial disease (PAD), marking a major advancement in R3 Vascular’s efforts to develop cutting-edge therapies for PAD patients.
In July 2024, Humacyte’s ATEV granted US FDA Regenerative Medicine Advanced Therapy designation for advanced Peripheral Arterial Disease.
Key Peripheral Arterial Disease companies such as Novo Nordisk, Hemostemix, AdvanceCor, and others are evaluating new drugs for Peripheral Arterial Disease to improve the treatment landscape.
Promising Peripheral Arterial Disease pipeline therapies in various stages of development include Semaglutide, ACP 01, Revacept, and others.
Peripheral Arterial Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Peripheral Arterial Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Arterial Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Peripheral Arterial Disease market.
Request for a sample report @ https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Peripheral Arterial Disease Companies
There are approx. 20+ key companies such as AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics, IsomAb, and others which are developing therapies for Peripheral Arterial Disease (PAD). The companies which have their Peripheral Arterial Disease (PAD) drug candidates in the most advanced stage, i.e. Phase III includes Novo Nordisk.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Peripheral Arterial Disease Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Peripheral Arterial Disease Therapies and Key Companies: Peripheral Arterial Disease Clinical Trials and advancements
Peripheral Arterial Disease Pipeline Therapeutic Assessment
• Peripheral Arterial Disease Assessment by Product Type
• Peripheral Arterial Disease By Stage
• Peripheral Arterial Disease Assessment by Route of Administration
• Peripheral Arterial Disease Assessment by Molecule Type
Download Peripheral Arterial Disease Sample report to know in detail about the Peripheral Arterial Disease treatment market @ Peripheral Arterial Disease Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Peripheral Arterial Disease Current Treatment Patterns
4. Peripheral Arterial Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Peripheral Arterial Disease Late-Stage Products (Phase-III)
7. Peripheral Arterial Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Peripheral Arterial Disease Discontinued Products
13. Peripheral Arterial Disease Product Profiles
14. Peripheral Arterial Disease Key Companies
15. Peripheral Arterial Disease Key Products
16. Dormant and Discontinued Products
17. Peripheral Arterial Disease Unmet Needs
18. Peripheral Arterial Disease Future Perspectives
19. Peripheral Arterial Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Peripheral Arterial Disease Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
